Skip to main content
SpringerLink
Log in

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Primary Cytoreductive Surgery for Advanced Stage Ovarian Cancer: indications for Radical Resection; Bristow R. Cancerología 2; Suplemento 1 (2007): s31-s36

  2. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L (2009) Gülten O; Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99(7):424–427

    Article  PubMed  Google Scholar 

  3. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371–1382

    Article  CAS  PubMed  Google Scholar 

  4. Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O (2014) Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg 151:347–353

    Article  CAS  PubMed  Google Scholar 

  5. Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104

    CAS  PubMed  Google Scholar 

  6. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974–979

    Article  CAS  PubMed  Google Scholar 

  7. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159–166

    Article  CAS  PubMed  Google Scholar 

  8. Whitney CW, Spirtos N (2009) Gynecologic oncology group surgical procedures manual. Philadelphia Gynecologic Oncology Group

  9. Chi DS, Ramirez PT, Teitcher JB, et al. (2007) Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol 25:4946–4951

    Article  PubMed  Google Scholar 

  10. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259

    Article  PubMed  Google Scholar 

  11. Aletti GD, Dowdy SC, Podratz KC, Cliby WA (2006) Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100:283–287

    Article  PubMed  Google Scholar 

  12. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103:1083–1090

    Article  PubMed  Google Scholar 

  13. Eisenkop SM, Spirtos NM, Friedman RL, et al. (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol 90:390–396

    Article  PubMed  Google Scholar 

  14. Chi DS, Eisenhauer EL, Zivanovic O, et al. (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31

    Article  PubMed  Google Scholar 

  15. Bukowski RM, Ozols RF, Markman M (2007) The management of recurrent ovarian cancer. Semin Oncol 34:S1–15

    Article  CAS  PubMed  Google Scholar 

  16. Makara AR, Coleman RL (2004) Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95:273–280

    Article  Google Scholar 

  17. Schorge J, McCann C, Del Carmen M (2010) Surgical Debulking of Ovarian Cancer: What Difference Does It Make? Rev Obstet Gynecol 3(3):111–117

    PubMed  PubMed Central  Google Scholar 

  18. Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265–274

    Article  PubMed  Google Scholar 

  19. Fotiou S, Aliki T, Petros Z, et al. (2009) Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer. Gynecol Oncol 114:178–182

    Article  PubMed  Google Scholar 

  20. Schorge JO, Wingo SN, Bhore R, et al. (2010) Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet 108:123–127

    Article  PubMed  Google Scholar 

  21. Harter P, du Bois A, Hahmann M, et al. (2006) Surgery in recur-rent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710

    Article  PubMed  Google Scholar 

  22. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295

    Article  PubMed  Google Scholar 

  23. Cotte E, Colomban O, Guitton J, et al. (2011) Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol 51(1):9–18

    Article  CAS  PubMed  Google Scholar 

  24. Alberts DS, Liu PY, Hannigan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955

    Article  CAS  PubMed  Google Scholar 

  25. Markman M, Bundy BN, Alberts DS, et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 19:1001–1007

    CAS  PubMed  Google Scholar 

  26. Armstrong DK, Bundy B, Wenzel L, et al. (2006) Intraperitoneal cisplatin and paclitaxel in Ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  27. Elit L, Oliver TK, Covens A, Kwon J, Fung MK, Hirte HW, Oza AM (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta- analysis. Cancer 109:692–702

    Article  CAS  PubMed  Google Scholar 

  28. Glehen O, Gilly FN (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemo hyperthermia. Lancet Oncol 5:219–228

    Article  PubMed  Google Scholar 

  29. Hettinga JV, Konings AW, Kampinga HH (1997) Reduction of cellular cisplatin resistance by hyperthermia — a review. Int J Hyperth 13:439–457

    Article  CAS  Google Scholar 

  30. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34(1):148–154

    Article  PubMed  Google Scholar 

  31. Chua TC, Moran BJ, Sugarbaker PH, et al. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456

    Article  PubMed  Google Scholar 

  32. Yan TD, Deraco M, Baratti D, et al. (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242

    Article  PubMed  Google Scholar 

  33. Elias D, Gilly F, Boutitie F, et al. (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68

    Article  PubMed  Google Scholar 

  34. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–2432

    Article  PubMed  Google Scholar 

  35. Glehen O, Gilly FN, Arvieux C, et al. (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377

    Article  PubMed  Google Scholar 

  36. Glehen O, Passot G, Villeneuve L, et al. (2014) GASTRICHIP: D2resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multi-center phase III study. BMC Cancer 14:183

    Article  PubMed  PubMed Central  Google Scholar 

  37. Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F (2012) Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence. Curr Pharm Des 18:3793–3803

    Article  CAS  PubMed  Google Scholar 

  38. Huo YR, Richards A, Liauw W, Morris DL (2015) Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surg Oncol 41(12):1578–1589. doi:10.1016/j.ejso.2015.08.172

    Article  CAS  PubMed  Google Scholar 

  39. Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:21

    Article  PubMed  PubMed Central  Google Scholar 

  40. Yoshida Y, Sasaki H, Kurokawa T, et al. (2005) Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up. Oncol Rep 13(1):121–125

    CAS  PubMed  Google Scholar 

  41. Rufián S, Muñoz-Casares FC, Briceño J, et al. (2006) Radical surgery peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316–324

    Article  PubMed  Google Scholar 

  42. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM (2009) Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer - 12-year single center experience. Eur J Surg Oncol 35(11):1186–1191

    Article  CAS  PubMed  Google Scholar 

  43. Pomel C, Ferron G, Lorimier G, et al. (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36(6):589–593

    Article  CAS  PubMed  Google Scholar 

  44. Roviello F, Pinto E, Corso G, et al. (2010) Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol 102(6):663–670

    Article  PubMed  Google Scholar 

  45. Parson EN, Lentz S, Russell G, et al. (2011) Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg 202(4):481–486

    Article  PubMed  Google Scholar 

  46. Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, et al. (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol 39:1109–1115

    Article  CAS  PubMed  Google Scholar 

  47. Helm CW, Richard SD, Pan J, et al. (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20(1):61–69

    Article  PubMed  Google Scholar 

  48. Deraco M, Kusamura S, Virzì S, et al. (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 122(2):215–220

    Article  PubMed  Google Scholar 

  49. Bakrin N, Bereder JM, Decullier E, et al. (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of566 patients. Eur J Surg Oncol 39:1435–1443

    Article  CAS  PubMed  Google Scholar 

  50. Gori J, Castaño R, Toziano M, et al. (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15:233–239

    Article  CAS  PubMed  Google Scholar 

  51. Vergote I, Tropé CG, Amant F, et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953

    Article  CAS  PubMed  Google Scholar 

  52. Kumar L, Hariprasad R, Kumar S, et al. (2010) Upfront surgery vs neoadjuvant, chemotherapy in advanced epithelial ovarian carcinoma (EOC): a randomized, study. IGCS 13. Prague (A824)

  53. Chi DS, Musa F, Dao F, et al. (2011) An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124(1):10–14

    Article  PubMed  Google Scholar 

  54. Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C (2010) Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer 20(8):1331–1340

    PubMed  Google Scholar 

  55. Morice P, Brehier-Ollive D, Rey A, et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-nonexposed study. Ann Oncol 14(1):74–77

    Article  CAS  PubMed  Google Scholar 

  56. Onda T, Kobayashi H, Nakanishi T, et al. (2009) Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol 113(1):57–62

    Article  PubMed  Google Scholar 

  57. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS (2006) Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 32(1):99–10

    Article  CAS  PubMed  Google Scholar 

  58. van der Vange N, van Goethem AR, Zoetmulder FAN, et al. (2000) Extensive cytoreductive surgery combined with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 26:663–668

    Article  PubMed  Google Scholar 

  59. Zanon C, Clara R, Chiappino I, et al. (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040–1045

    Article  PubMed  Google Scholar 

  60. Cotte E, Glehen O, Mohamed F, et al. (2007) Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31:1813–1820

    Article  PubMed  Google Scholar 

  61. Di Giorgio A, Naticchioni E, Biacchi D, et al. (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113(2):315–325

    Article  PubMed  Google Scholar 

  62. Carrabin N, Mithieux F, Meeus P, et al. (2010) Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer 97(4):E23–E32

    CAS  PubMed  Google Scholar 

  63. Königsrainer I, Beckert S, Becker S, et al. (2011) Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbeck's Arch Surg 396(7):1077–1081

    Article  Google Scholar 

  64. Frenel JS, Leux C, Pouplin L, et al. (2011) Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. J Surg Oncol 103(1):10–16

    Article  PubMed  Google Scholar 

  65. Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P (2009) Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol 19(7):2352–2359

  66. Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 1:54–61. doi:10.3802/jgo.2015.26.1.54

    Article  Google Scholar 

  67. Munoz-Casares FC, Rufian S, Rubio MJ, et al. (2009) The role of hyper-thermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 11:753–759

    Article  PubMed  Google Scholar 

  68. Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A (2011) The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 16:74–79

    CAS  PubMed  Google Scholar 

  69. Fagotti A, Costantini B, Petrillo M, et al. (2012) Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-up. Gynecol Oncol 127:502–505

    Article  PubMed  Google Scholar 

  70. Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM (2014) Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improvesprogression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol 110(6):661–665. doi:10.1002/jso.23688

    Article  PubMed  Google Scholar 

  71. Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ (2015) Parrilla The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrentepithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 22(3):987–993. doi:10.1245/s10434-014-4049-z

    Article  PubMed  Google Scholar 

  72. Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94(11):1408–1414

    Article  CAS  PubMed  Google Scholar 

  73. Raspagliesi F, Kusamura S, Campos Torres JC, et al. (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32:671–675

    Article  CAS  PubMed  Google Scholar 

  74. Kim JH, Lee JM, Ryu KS, et al. (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101(2):149–155

    CAS  PubMed  Google Scholar 

  75. Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907

    Article  PubMed  Google Scholar 

  76. Glehen O, Gilly FN, Boutitie F, et al. (2010) Toward curative treatment of peritoneal carcinomatosis from non- ovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116:5608–5618

    Article  PubMed  Google Scholar 

  77. Elias DM, Ouellet JF (2001) Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am 10:915–933

    CAS  PubMed  Google Scholar 

  78. Hettinga JV, Lemstra W, Meijer C, Dam WA, Uges DR, Konings AW, De Vries EG, Kampinga HH (1997) Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells. Br J Cancer 75:1735–1743

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Fortis Hospital, Bangalore, India

    Aditi Bhatt

  2. Hospices Civils de Lyon, Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, 69495, Pierre-Bénite, Cedex, France

    Olivier Glehen

  3. Université Lyon 1, EMR 3738, 69600, Oullins, France

    Olivier Glehen

Authors
  1. Aditi Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Glehen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Glehen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhatt, A., Glehen, O. The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. Indian J Surg Oncol 7, 188–197 (2016). https://doi.org/10.1007/s13193-016-0501-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13193-016-0501-9

Keywords

Search

Navigation